WS Value & Dossier GmbH
Your specialists for market access and reimbursement
How the German AMNOG process works
Value & Dossier GmbH advises pharmaceutical companies and biotechnology companies throughout the AMNOG process and on all matters relating to market access and reimbursement. Based on our long-standing expertise, we advise you on the development of the best strategy, the preparation of your benefit dossier for the G-BA assessment and the price negotiations with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband).
Your success is what drives us. We will make sure that your new product will be reimbursed in the best possible way.
Our Services
Strategic Market Access Consulting
German Benefit Assessment (AMNOG)
AMNOG price negotiations 
Reference pricing for pharmaceuticals
European Health Technology Assessment (EU-HTA)
European Reference Price Calculator
Reimbursement of Medical Devices
HTA Services
Celebrating 10 Years of WS Value & Dossier!
„Exactly 10 years ago, we started out with a vision, a great deal of courage and a firm belief in our idea. Today, we look back proudly on a decade full of exciting projects, shared challenges and successes.
This anniversary is a milestone for us that would not have been possible without the trust of our clients, the commitment of our great team and the support of our partners. We would like to express our heartfelt thanks!“
– Dr. Willi Schnorpfeil, Managing Partner
“We offer individual and company-specific solutions focussing on the value of the product while implementing it accordingly in the required benefit dossiers.”
Your team of specialists from Value & Dossier
f.l.t.r. Julia Gerbeth M. Sc., Dr. Hanna Klimek, Dr. Sandra Kiehlmeier, Dr. Willi Schnorpfeil, Christopher Bell M. Sc., Anna Lenhart M. Sc., Christian Schneider, Sandra Fraatz, Michelle Woods M. Sc.
Recent Articles
Pharmaceutical companies with R&D in Germany – Benefit for price negotiations
Figure 1: Different price guidelines apply for the AMNOG price negotiations if ≥ 5 % of
European Reference Pricing is discontinued in Germany
Figure 1: Number of reference prices used by each country Changes to the German pricing
Confidential reimbursement amount – Only for pharmaceutical companies with R&D in Germany
Figure 1: Requirements, pros and cons for the confidential reimbursement amount in Germany Confidential reimbursement